-
2023-503766-24-00
11
2026-05-26
Moderate to Severe Plaque Psoriasis
-
2025-523431-19-00
4
2026-05-20
Idiopathic Pulmonary Fibrosis (IPF)
-
2025-521108-23-00
5
2026-05-19
Chronic Obstructive Pulmonary Disease
-
2025-522107-18-00
4
2026-05-19
Locally advanced or metastatic Non-Small Cell Lung Cancer
-
2024-516993-31-00
5
2026-05-11
Renal Cell Carcinoma
-
2025-520997-21-00
4
2026-05-08
Psoriatic arthritis
-
2025-523552-31-00
5
2026-05-07
Systemic Lupus Erythematosus
-
2025-523914-10-00
6
2026-04-30
Critical illness
-
2025-522440-41-00
4
2026-04-27
Hidradenitis Suppurativa
-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2025-522583-32-00
5
2026-04-13
Cold-Induced Urticaria and Symptomatic Dermographism
-
2025-523085-24-00
5
2026-04-13
Biliary Tract Cancer
-
2025-523263-37-00
10
2026-04-08
Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal
-
2025-523013-28-00
4
2026-04-07
Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-521973-16-00
9
2026-03-31
Netherton Syndrome
-
2024-516544-26-00
4
2026-03-30
acute ischemic stroke
-
2025-522544-40-00
5
2026-03-27
Hereditary transthyretin-mediated amyloidosis with polyneuropathy
-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2025-522674-36-00
5
2026-03-24
Metabolic Dysfunction-Associated Steatotic Liver Disease
-
2025-523141-10-00
4
2026-03-20
Active Psoriatic Arthritis
-
2024-519344-32-00
9
2026-03-16
Non-small Cell Lung Cancer
-
2025-521621-33-00
6
2026-03-16
Melanoma